2025-02-28 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**0. Executive Summary:**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  This report analyzes MRK's performance against the S&P 500 (VOO), examining its recent price movements, financial indicators, and earnings.  The analysis reveals a significant underperformance relative to the S&P 500, although recent financial indicators show strong profitability.


**1. Performance Comparison with S&P 500 (VOO):**

Merck & Co Inc (MRK) is a large-cap pharmaceutical company developing and manufacturing medicines and vaccines.  Its cumulative return of 49.06% significantly lags behind the S&P 500's cumulative return of 112.87% over the analyzed period. The difference is -63.8%, placing it at the 16.1th percentile of its historical range of relative underperformance (-85.4% to 48.5%).

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | -2.0% | 11.8% | -0.1 | 109.9 |
| 2016-2018  | 46.0% | 11.8% | 0.5 | 153.8 |
| 2017-2019  | 44.0% | 11.8% | 0.3 | 188.1 |
| 2018-2020  | 32.0% | 9.4% | 0.2 | 174.6 |
| 2019-2021  | 3.0% | 14.3% | 0.2 | 177.6 |
| 2020-2022  | 47.0% | 14.3% | 0.2 | 265.4 |
| 2021-2023  | 55.0% | 14.3% | 0.3 | 268.1 |
| 2022-2024  | 21.0% | 9.5% | 0.3 | 251.3 |
| 2023-2025  | -37.0% | 9.5% | 0.1 | 228.8 |

The analysis shows significant volatility in CAGR and Alpha, indicating periods of both outperformance and underperformance relative to the market (Beta consistently above 1 suggesting higher volatility than the market).


**2. Recent Price Movement:**

* **Closing Price:** $90.58
* **5-Day Moving Average:** $90.43
* **20-Day Moving Average:** $89.40
* **60-Day Moving Average:** $96.11

The price is slightly above the 5-day moving average, suggesting recent upward momentum. However, it is below both the 20-day and 60-day moving averages, indicating a potential short-term correction from higher levels.  The recent price change of $1.34 (from $89.38) reflects a significant single-day jump, which may indicate a market reaction to a news event.


**3. Technical Indicators and Expected Return:**

* **RSI:** 57.45 (Neither overbought nor oversold)
* **PPO:** 0.89 (Positive, suggesting upward momentum)
* **Delta_Previous_Relative_Divergence:** +10.4 (Short-term upward trend)
* **Expected Return (2+ years):** 37.9% (significantly higher than the S&P 500 implied return)


The relatively high expected return highlights potential for outperformance if held long-term, despite recent underperformance.  The positive PPO and short-term relative divergence indicate potential for continued upward momentum.  The significant price increase of $1.34 might indicate a positive market reaction.


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2024-11-06 | 1.25 | $16.66 B     |
| 2024-08-05 | 2.15 | $16.11 B     |
| 2024-05-03 | 1.88 | $15.78 B     |
| 2023-11-03 | 1.87 | $15.96 B     |
| 2024-11-06 | 1.87 | $15.96 B     | *(Note: Duplicate entry - likely an error in the data)*

Revenue remains relatively stable, while EPS shows some fluctuation.  The duplicated entry needs clarification.  Further investigation into the cause of EPS volatility is recommended.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue   | Profit Margin |
|---------|-----------|---------------|
| 2024-12-31 | $15.62B  | 75.50%        |
| 2024-09-30 | $16.66B  | 75.51%        |
| 2024-06-30 | $16.11B  | 76.76%        |
| 2024-03-31 | $15.78B  | 77.56%        |
| 2023-12-31 | $14.63B  | 73.26%        |

**Capital and Profitability:**

| Quarter | Equity    | ROE       |
|---------|-----------|-----------|
| 2024-12-31 | $46.31B  | 8.08%     |
| 2024-09-30 | $44.50B  | 7.09%     |
| 2024-06-30 | $43.58B  | 12.52%    |
| 2024-03-31 | $40.36B  | 11.80%    |
| 2023-12-31 | $37.58B  | -3.26%    |

High and stable profit margins indicate strong operational efficiency. ROE shows fluctuations, but generally positive, suggesting effective use of equity.


**6. Overall Analysis:**

MRK has significantly underperformed the S&P 500 over the analyzed period, despite showing strong profitability. Recent price movements suggest potential short-term correction, but positive technical indicators and a high projected long-term return warrant consideration.  The fluctuating EPS and need for clarification on duplicate entries in the earnings data require further investigation.  The overall financial health appears robust, characterized by high profit margins and generally positive ROE.  A deeper dive into the reasons for the underperformance relative to the market is necessary for a comprehensive investment decision.  Investors should carefully consider the inherent risks in the pharmaceutical sector and the volatility associated with MRK's stock price before making any investment decisions.
